M03-613 was a 2-year, randomized controlled clinical trial in antiretroviral-naive, HIV-infected subjects who, after undergoing initial induction therapy with a standard highly active antiretroviral ...

Among treatment-naive adults with advanced HIV disease, integrase inhibitors are a preferred first-line therapy over protease inhibitors.

Key goals of EHE include, from 2017 to the end of 2025, reducing new HIV infections and diagnoses by 75%, increasing viral suppression among PWH to 95%, and increasing good or better self-rated health ...

Weight gain associated with integrase strand transfer inhibitor-based antiretroviral therapy (ART) may be mitigated or reversed over time by switching to protease inhibitor-based ART. For patients ...

Gilead Sciences Inc. recently disclosed details on the work that led to the discovery of elunonavir (GS-1156), an unboosted HIV protease inhibitor currently in phase I studies.